[go: up one dir, main page]

TW200501975A - An agent for upregulating physiological function during exercise - Google Patents

An agent for upregulating physiological function during exercise

Info

Publication number
TW200501975A
TW200501975A TW093113807A TW93113807A TW200501975A TW 200501975 A TW200501975 A TW 200501975A TW 093113807 A TW093113807 A TW 093113807A TW 93113807 A TW93113807 A TW 93113807A TW 200501975 A TW200501975 A TW 200501975A
Authority
TW
Taiwan
Prior art keywords
agent
during exercise
upregulating
fatigue
physiological function
Prior art date
Application number
TW093113807A
Other languages
English (en)
Inventor
Taeko Iino
Hiroaki Tanaka
Keisuke Sawaki
Natsue Koikawa
Yoshinobu Kiso
Original Assignee
Suntory Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Suntory Ltd filed Critical Suntory Ltd
Publication of TW200501975A publication Critical patent/TW200501975A/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/13—Coniferophyta (gymnosperms)
    • A61K36/15—Pinaceae (Pine family), e.g. pine or cedar
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Botany (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Nutrition Science (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Toxicology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biochemistry (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Tea And Coffee (AREA)
TW093113807A 2003-06-19 2004-05-17 An agent for upregulating physiological function during exercise TW200501975A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2003174542 2003-06-19

Publications (1)

Publication Number Publication Date
TW200501975A true TW200501975A (en) 2005-01-16

Family

ID=33534793

Family Applications (1)

Application Number Title Priority Date Filing Date
TW093113807A TW200501975A (en) 2003-06-19 2004-05-17 An agent for upregulating physiological function during exercise

Country Status (9)

Country Link
US (1) US20070099853A1 (zh)
EP (1) EP1639902A4 (zh)
JP (1) JPWO2004112510A1 (zh)
KR (1) KR20060021383A (zh)
CN (1) CN1809285A (zh)
AU (1) AU2004249023A1 (zh)
CA (1) CA2529462A1 (zh)
TW (1) TW200501975A (zh)
WO (1) WO2004112510A1 (zh)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006193435A (ja) * 2005-01-11 2006-07-27 Kagome Co Ltd 疲労改善剤
JP4739161B2 (ja) * 2005-10-26 2011-08-03 花王株式会社 持久力向上剤
JP2007306872A (ja) * 2006-05-19 2007-11-29 Suntory Ltd プロアントシアニジン含有茶飲料
PL2068901T3 (pl) * 2006-10-05 2019-05-31 Dsm Ip Assets Bv Zastosowanie hydroksytyrozolu do zmniejszenia ilości kwasu mlekowego w osoczu
EP2022344A1 (en) * 2007-08-02 2009-02-11 Nestec S.A. Reduction of fatigue as a result of exercise
JP2009183257A (ja) * 2008-02-08 2009-08-20 Toyo Shinyaku Co Ltd 食品の風味を改善する方法及び風味が改善された食品
CN101756090B (zh) * 2009-12-18 2012-08-01 中国人民武装警察部队后勤学院 体力恢复剂及用途
CN103462037B (zh) * 2013-09-13 2015-11-25 浙江农林大学 一种天然食品添加剂
CN104686693A (zh) * 2015-03-17 2015-06-10 黑龙江绿知都生物科技开发有限公司 一种发酵茶饮料的生产工艺
CN104856173B (zh) * 2015-04-24 2017-05-17 南京林业大学 一种原花色素天然保健饮料及其制备方法
JP6646369B2 (ja) * 2015-06-25 2020-02-14 株式会社東洋新薬 抗疲労剤
JP6829487B2 (ja) * 2019-07-11 2021-02-10 株式会社東洋新薬 抗疲労剤

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3260134B2 (ja) * 1999-10-08 2002-02-25 信孝 鈴木 月経困難症、子宮内膜症の治療薬
AUPQ780300A0 (en) * 2000-05-23 2000-06-22 Gillam, Ian Dr Dosage formula/guidelines for a sports antioxidant
JP2002119221A (ja) * 2000-10-12 2002-04-23 Kikkoman Corp 馬用体質改善剤及び馬の体質改善方法
JP2002338464A (ja) * 2001-05-14 2002-11-27 Kikkoman Corp 筋肉萎縮抑制剤
JP2003095964A (ja) * 2001-09-21 2003-04-03 Toyo Shinyaku:Kk 抗ストレス剤
JP2003334022A (ja) * 2002-05-17 2003-11-25 Toyo Shinyaku:Kk 持久力向上用食品組成物
CA2487588C (en) * 2002-05-31 2011-09-27 Suomen Ravitsemusinstituutti Oy Drink composition and a method for composing a drink

Also Published As

Publication number Publication date
KR20060021383A (ko) 2006-03-07
US20070099853A1 (en) 2007-05-03
AU2004249023A1 (en) 2004-12-29
EP1639902A1 (en) 2006-03-29
WO2004112510A1 (ja) 2004-12-29
JPWO2004112510A1 (ja) 2006-07-27
EP1639902A4 (en) 2009-04-15
CN1809285A (zh) 2006-07-26
CA2529462A1 (en) 2004-12-29

Similar Documents

Publication Publication Date Title
TW200501975A (en) An agent for upregulating physiological function during exercise
WO2005027993A3 (en) Vascular access preservation in hemodialysis patients
WO2006121518A3 (en) Electrical devices, anti-scarring agents, and therapeutic compositions
SG161234A1 (en) A method and composition for nutritionally improving glucose control and insulin action
MXPA05009694A (es) Metodos para mejorar la calidad de la piel.
WO2004073741A8 (ja) インターロイキン－６アンタゴニストを含有する脊髄損傷治療剤
WO2005095959A3 (en) Methods for treating dermatological conditions in a patient
MXPA05006629A (es) Formas de dosificacion que contienen un inhibidor de bomba de protones, un nsaid y un amortiguador.
IL154318A0 (en) Pharmaceutical compositions for the treatment of movement disorders
WO2007011874A3 (en) Formulation and method for administration of ophthalmologically active agents
PT1228708E (pt) Fraccao proteica basica de derivados de leite como agentes para a reducao da pressao alta sanguinea
EP1727578A4 (en) TROCAR CANNULA COMPLEX, CANNULA, AND METHOD FOR DISTRIBUTING BIOLOGICALLY ACTIVE AGENTS IN MINIMAL-INVASIVE SURGERY
TR200200179T2 (tr) Kas yorgunluğunun önlenmesi ve kas adaptasyonu için bileşim
AU2003259112A8 (en) Enzymatic process for the preparation of foods, feedstuffs and ingredients therefor
PT1596868E (pt) Método para o tratamento de insuficiência cardíaca grave e medicamento associado
EP1952701A3 (en) Improving longevity and the condition of elderly cats
WO2004093995A3 (en) Use of antioxidants to treat bone loss disorders
WO2005113016A3 (en) Modulation of glucose-6-phosphatase translocase expression
SG153661A1 (en) Formulation and methods for the treatment of thrombocythemia
TW200503666A (en) Treatment of type 1 diabetes with pde5 inhibitors
WO2003082203A3 (en) Elastin prevents occlusion of body vessels by vascular smooth muscle cells
PL1861080T3 (pl) Idebenon do leczenia dystrofii mięśniowych
WO2005034858A8 (en) Compositions and methods for treatment of muscle pain and muscle wasting
WO2005020984A3 (en) Method of reducing the risk of oxidative stress
WO2006127759A3 (en) Antioxidant supplement composition and method of use